Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Molecular markers to predict outcome to antiangiogenic therapies in colorectal cancer: current evidence and future perspectives.

Custodio A, Barriuso J, de Castro J, Martínez-Marín V, Moreno V, Rodríguez-Salas N, Feliu J.

Cancer Treat Rev. 2013 Dec;39(8):908-24. doi: 10.1016/j.ctrv.2013.02.004. Review.

PMID:
23510598
2.

Biomarkers to predict the clinical efficacy of bevacizumab in cancer.

Jubb AM, Harris AL.

Lancet Oncol. 2010 Dec;11(12):1172-83. doi: 10.1016/S1470-2045(10)70232-1. Review.

PMID:
21126687
3.

Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients.

Loupakis F, Bocci G, Pasqualetti G, Fornaro L, Salvatore L, Cremolini C, Masi G, Danesi R, Del Tacca M, Falcone A.

Curr Cancer Drug Targets. 2010 Feb;10(1):37-45. Review.

PMID:
20088795
5.

Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.

Grothey A, Ellis LM.

Cancer J. 2008 May-Jun;14(3):170-7. doi: 10.1097/PPO.0b013e318178d9de. Review.

PMID:
18536556
6.

The evolving role of VEGF-targeted therapies in the treatment of metastatic colorectal cancer.

Fakih M.

Expert Rev Anticancer Ther. 2013 Apr;13(4):427-38. doi: 10.1586/era.13.20. Review.

PMID:
23432698
7.

Biomarkers for antitumor activity of bevacizumab in gastric cancer models.

Yamashita-Kashima Y, Fujimoto-Ouchi K, Yorozu K, Kurasawa M, Yanagisawa M, Yasuno H, Mori K.

BMC Cancer. 2012 Jan 25;12:37. doi: 10.1186/1471-2407-12-37.

8.

Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer.

Troiani T, Martinelli E, Orditura M, De Vita F, Ciardiello F, Morgillo F.

Expert Opin Investig Drugs. 2012 Jul;21(7):949-59. doi: 10.1517/13543784.2012.689287. Review.

PMID:
22612461
9.

Use of bevacizumab in metastatic colorectal cancer: report from the Mexican opinion and analysis forum on colorectal cancer treatment with bevacizumab (September 2009).

Zinser-Sierra JW, Rodríguez-Ramírez S, Villalobos-Valencia R, Ramírez-Márquez M.

Drugs R D. 2011;11(2):101-11. doi: 10.2165/11590440-000000000-00000. Review.

10.

Antiangiogenesis agents in colorectal cancer.

Hubbard J, Grothey A.

Curr Opin Oncol. 2010 Jul;22(4):374-80. doi: 10.1097/CCO.0b013e328339524e. Review.

PMID:
20375894
11.

Future directions in the use of antiangiogenic agents in patients with colorectal cancer.

Hoff PM.

Semin Oncol. 2004 Dec;31(6 Suppl 17):17-21. Review.

PMID:
15696026
12.
13.

Recent concepts of antiangiogenic therapy.

Konno H, Yamamoto M, Ohta M.

Surg Today. 2010 Jun;40(6):494-500. doi: 10.1007/s00595-009-4150-2. Review.

PMID:
20496129
14.

Targeting angiogenesis: progress with anti-VEGF treatment with large molecules.

Grothey A, Galanis E.

Nat Rev Clin Oncol. 2009 Sep;6(9):507-18. doi: 10.1038/nrclinonc.2009.110. Review.

PMID:
19636328
15.

Antiangiogenic therapy in malignant glioma: promise and challenge.

Sathornsumetee S, Rich JN.

Curr Pharm Des. 2007;13(35):3545-58. Review.

PMID:
18220791
16.

[Anti-angiogenic treatment and colorectal cancer].

André T, Tournigand C, Abbas F, Louvet C, de Gramont A; Gercor (French Oncology Research Group)..

Bull Cancer. 2007 Jul;94 Spec No:S211-9. Review. French.

PMID:
17846007
17.

Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent.

Shin SJ, Hwang JW, Ahn JB, Rha SY, Roh JK, Chung HC.

Invest New Drugs. 2013 Feb;31(1):1-13. doi: 10.1007/s10637-012-9817-7.

PMID:
22539090
18.

Bevacizumab in colorectal cancer: current and future directions.

Yeung Y, Tebbutt NC.

Expert Rev Anticancer Ther. 2012 Oct;12(10):1263-73. doi: 10.1586/era.12.104. Review.

PMID:
23113577
19.

Bevacizumab: antiangiogenic cancer therapy.

Culy C.

Drugs Today (Barc). 2005 Jan;41(1):23-36. Review.

PMID:
15753967
20.

Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab.

Guijarro-Muñoz I, Sánchez A, Martínez-Martínez E, García JM, Salas C, Provencio M, Alvarez-Vallina L, Sanz L.

Med Oncol. 2013;30(2):572. doi: 10.1007/s12032-013-0572-1.

PMID:
23579861
Items per page

Supplemental Content

Support Center